$CTXR News

Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Citius Oncology Ships First International Order of LYMPHIR™ to Europe

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals Secures $5M Through Equity Offering

Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

Citius Pharmaceuticals shares are trading lower after the company announced a $5 million registered direct offering.

UPDATE: Reported Earlier, Citius Pharma Prices $5M Offering Of 5,076,143 Shares At A Price Of $0.985/Share

We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

Citius Pharmaceuticals shares are trading higher after the company provided a commercial update on the U.S. launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma.

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

Citius Pharmaceuticals shares are trading higher after the company announced topline results from investigator‑initiated Phase 1 Study of LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers.

Citius Oncology Announces Data From Phase 1 Clinical Study Of Direct T-Regulatory Cell Depletion Activity Of LYMPHIR Shows 24% Objective Response Rate, 48% Clinical Benefit Rate In Participants With Recurrent Or Refractory Gynecologic Cancers

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Oncology Announces Topline Results From Investigator‑Initiated Phase 1 Trial Of LYMPHIR Administered Prior To Commercial CD19‑Directed CAR‑T Therapy In High‑Risk DLBCL; Co Says LYMPHIR Was Well-Tolerated With No Dose-Limiting Toxicities Observed